533 Bryant Street
54 articles with Horizon Therapeutics
Horizon Therapeutics plc announced that the Company will participate in the following upcoming conferences
Horizon Therapeutics plc announced that the Company will participate in the following conference in May:
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”).
Horizon Therapeutics plc announced that it has been recognized as one of the Best Workplaces in Ireland 2021 by Great Place to Work Ireland, ranking No. 12 in the small company category.
Horizon Therapeutics plc Shines a Light on Rare Disease with the Launch of the #RAREis Photobooth to Benefit Make-A-Wish®
March kicks-off the company’s donation match through Uplifting Athletes’ Reps for Rare Diseases program to further research for new therapies
Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes
Medidata, a Dassault Systèmes company and the global leader in creating end-to-end solutions to support the entire clinical development process, announced its expanded partnership with Horizon Therapeutics plc.
Horizon Therapeutics plc announced that the Company will participate in the following conferences in December:
11/6/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
Horizon to host an online discussion with Puja Khanna, M.D., M.P.H., co-primary investigator for RECIPE, on Nov. 10 at 7 p.m. ET
Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
Horizon Therapeutics plc announced that Karin Rosén, M.D., Ph.D., has joined the company as executive vice president, research and development and chief scientific officer, reporting directly to Tim Walbert, chairman, president and chief executive officer.
AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization, announced that its partnership with Horizon Therapeutics plc is expanding to produce Horizon's Thyroid Eye Disease treatment, TEPEZZA, at AGC's new facility in Boulder, CO.
Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the Crain’s Chicago Business 2020 Best Places to Work in Chicago list. “It’s a tremendous honor that Crain’s Chicago Business ranked us among the Best Places to Work in Chicago where many Horizon employees live and work,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Despite these challenging times, working at
Horizon Therapeutics plc announced the pricing of its underwritten public offering of 11,800,000 of its ordinary shares at a price to the public of $71.00 per share.
New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)
89 percent of patients who received placebo during the OPTIC Phase 3 clinical trial and then received TEPEZZA in the OPTIC-X extension trial achieved clinically significant proptosis reduction with an average of 12 months of disease, compared with six months in OPTIC
U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of Life
In an analysis accepted for presentation at the American Association of Clinical Endocrinologists (AACE) Annual Scientific & Clinical Congress, physicians cite psychological well-being and ability to function in social situations as most impacted by the disease
Horizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA™ Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-Year 2020 Net Sales Guidance
First-Quarter 2020 Net Sales of $355.9 Million Increased 27 Percent; First-Quarter 2020 GAAP Net Loss of $13.6 Million; Adjusted EBITDA of $107.2 Million
Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment
4/2/2020Biopharma companies from across the globe provide updates on their pipelines and business practices.
TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
Data presented as part of ENDO 2020 demonstrates proptosis response regardless of age, gender and smoking status
3/9/2020Although March looks to be a busy month for the U.S. Food and Drug Administration, several of the PDUFA dates for this week were for drugs under Priority Review.